Expression and Prognostic Value Identification of Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2) in Brain Low-Grade Glioma

References

• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16(Suppl 4):iv1–iv63. doi:10.1093/neuonc/nou223
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-1
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. doi:10.1007/s00401-007-0243-4
   PubMed Web of Science ®Google Scholar
• Gnekow AK, Walker DA, Kandels D, et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (</=16 years) low grade glioma - A final report. Eur J Cancer. 2017;81:206–225.
   PubMed Web of Science ®Google Scholar
• Forst DA, Nahed BV, Loeffler JS, Batchelor TT. Low-grade gliomas. Oncologist. 2014;19:403–413. doi:10.1634/theoncologist.2013-0345
   PubMed Web of Science ®Google Scholar
• Morshed RA, Young JS, Hervey-Jumper SL, Berger MS. The management of low-grade gliomas in adults. J Neurosurg Sci. 2019;63:450–457. doi:10.23736/S0390-5616.19.04701-5
   PubMed Web of Science ®Google Scholar
• Afra D, Osztie E, Sipos L, Vitanovics D. Preoperative history and postoperative survival of supratentorial low-grade astrocytomas. Br J Neurosurg. 1999;13:299–305. doi:10.1080/02688699943727
   PubMed Web of Science ®Google Scholar
• Islam T, Rahman MR, Shuvo MA, Shahjaman M, Islam MR, Karim MR. Drug repositioning and biomarkers in low-grade glioma via bioinformatics approach. Inform Med Unlocked. 2019;17:100250. doi:10.1016/j.imu.2019.100250
   Google Scholar
• Tibbetts AS, Appling DR. Compartmentalization of mammalian folate-mediated one-carbon metabolism. Annu Rev Nutr. 2010;30:57–81.
   PubMed Web of Science ®Google Scholar
• Gustafsson R, Jemth AS, Gustafsson NM, et al. Crystal structure of the emerging cancer target MTHFD2 in complex with a substrate-based inhibitor. Cancer Res. 2017;77:937–948. doi:10.1158/0008-5472.CAN-16-1476
   PubMed Web of Science ®Google Scholar
• Tedeschi PM, Vazquez A, Kerrigan JE, Bertino JR. Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) overexpression is associated with tumor cell proliferation and is a novel target for drug development. Mol Cancer Res. 2015;13:1361–1366. doi:10.1158/1541-7786.MCR-15-0117
   PubMed Web of Science ®Google Scholar
• Nishimura T, Nakata A, Chen X, et al. Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2. Oncogene. 2019;38:2464–2481. doi:10.1038/s41388-018-0589-1
   PubMed Web of Science ®Google Scholar
• Koufaris C, Valbuena GN, Pomyen Y, et al. Systematic integration of molecular profiles identifies miR-22 as a regulator of lipid and folate metabolism in breast cancer cells. Oncogene. 2016;35(21):2766–2776. doi:10.1038/onc.2015.333
   PubMed Web of Science ®Google Scholar
• Pikman Y, Puissant A, Alexe G, et al. Targeting MTHFD2 in acute myeloid leukemia. J Exp Med. 2016;213:1285–1306. doi:10.1084/jem.20151574
   PubMed Web of Science ®Google Scholar
• Lehtinen L, Ketola K, Makela R, et al. High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. Oncotarget. 2013;4:48–63. doi:10.18632/oncotarget.756
   PubMedGoogle Scholar
• Liu M, Xu Z, Du Z, et al. The identification of key genes and pathways in glioma by bioinformatics analysis. J Immunol Res. 2017;2017:1–9.
   Web of Science ®Google Scholar
• Wang S, Jin F, Fan W. Gene expression meta-analysis in diffuse low-grade glioma and the corresponding histological subtypes. Sci Rep. 2017;7:11741. doi:10.1038/s41598-017-12087-y
   PubMed Web of Science ®Google Scholar
• Nilsson R, Jain M, Madhusudhan N. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun. 2014;5:3128. doi:10.1038/ncomms4128
   PubMed Web of Science ®Google Scholar
• Wei Y, Liu P, Li Q, et al. The effect of MTHFD2 on the proliferation and migration of colorectal cancer cell lines. Onco Targets Ther. 2019;12:6361–6370. doi:10.2147/OTT.S210800
   PubMed Web of Science ®Google Scholar
• Yu C, Yang L, Cai M, et al. Down-regulation of MTHFD2 inhibits NSCLC progression by suppressing cycle-related genes. J Cell Mol Med. 2020;24(2):1568–1577. doi:10.1111/jcmm.14844
   PubMed Web of Science ®Google Scholar
• Lin H, Huang B, Wang H, et al. MTHFD2 overexpression predicts poor prognosis in renal cell carcinoma and is associated with cell proliferation and vimentin-modulated migration and invasion. Cell Physiol Biochem. 2018;51(2):991–1000. doi:10.1159/000495402
   PubMedGoogle Scholar
• Liu X, Huang Y, Jiang C, et al. Methylenetetrahydrofolate dehydrogenase 2 overexpression is associated with tumor aggressiveness and poor prognosis in hepatocellular carcinoma. Dig Liver Dis. 2016;48(8):953–960. doi:10.1016/j.dld.2016.04.015
   PubMedGoogle Scholar
• He H, Li P-C, Jia W, Hu B, Ji C-S. High expression of Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2) in Esophageal squamous cell carcinoma and its clinical prognostic significance. Med Sci Monit. 2020;26:e920259. doi:10.12659/MSM.920259
   PubMed Web of Science ®Google Scholar
• Liu F, Liu Y, He C, et al. Increased MTHFD2 expression is associated with poor prognosis in breast cancer. Tumour Biol. 2014;35(9):8685–8690. doi:10.1007/s13277-014-2111-x
   PubMedGoogle Scholar
• Xu T, Zhang K, Shi J, et al. MicroRNA-940 inhibits glioma progression by blocking mitochondrial folate metabolism through targeting of MTHFD2. Am J Cancer Res. 2019;9:250–269.
   PubMed Web of Science ®Google Scholar
• Gao WZ, Guo LM, Xu TQ, Yin YH, Jia F. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients. J Transl Med. 2018;16:368. doi:10.1186/s12967-018-1744-8
   PubMed Web of Science ®Google Scholar
• Green NH, Galvan DL, Badal SS, et al. MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma. Oncogene. 2019;38(34):6211–6225. doi:10.1038/s41388-019-0869-4
   PubMed Web of Science ®Google Scholar
• Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med. 1948;238(23):787–793. doi:10.1056/NEJM194806032382301
   PubMed Web of Science ®Google Scholar
• Yan Y, Zhang D, Lei T, et al. MicroRNA-33a-5p suppresses colorectal cancer cell growth by inhibiting MTHFD2. Clin Exp Pharmacol Physiol. 2019;46:928–936. doi:10.1111/1440-1681.13125
   PubMed Web of Science ®Google Scholar
• Li SM, Zhao YQ, Hao YL, Liang YY. Upregulation of miR-504-3p is associated with favorable prognosis of acute myeloid leukemia and may serve as a tumor suppressor by targeting MTHFD2. Eur Rev Med Pharmacol Sci. 2019;23:1203–1213.
   PubMed Web of Science ®Google Scholar
• Ju HQ, Lu YX, Chen DL. Modulation of redox homeostasis by inhibition of MTHFD2 in colorectal cancer: mechanisms and therapeutic implications. J Natl Cancer Inst. 2019;111:584–596. doi:10.1093/jnci/djy160
   PubMedGoogle Scholar